Received: from AMS1EPF0000004B.eurprd04.prod.outlook.com (2603:10a6:400:293:cafe::7a) by CW1P123CA0003.outlook.office365.com (2603:10a6:400:293::13) with Microsoft SMTP Server (version=TLS1_3, cipher=TLS_AES_256_GCM_SHA384) id 15.20.9870.25 via Frontend Transport; Tue, 5 May 2026 09:56:46 +0000 Received: from CW1P123CA0003.GBRP123.PROD.OUTLOOK.COM (2603:10a6:400:293::13) by DU4PR02MB11713.eurprd02.prod.outlook.com (2603:10a6:10:637::24) with Microsoft SMTP Server (version=TLS1_2, cipher=TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384) id 15.20.9870.25; Tue, 5 May 2026 09:56:46 +0000 Received: from westeu12-emailsignatures-cloud.codetwo.com (13.93.42.39) by AMS1EPF0000004B.mail.protection.outlook.com (10.167.16.136) with Microsoft SMTP Server (version=TLS1_2, cipher=TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384) id 15.20.9891.9 via Frontend Transport; Tue, 5 May 2026 09:56:45 +0000 Received: from AM0PR07CU002.outbound.protection.outlook.com (40.93.65.71) by westeu12-emailsignatures-cloud.codetwo.com with CodeTwo SMTP Server (TLS12) via SMTP; Tue, 05 May 2026 09:56:44 +0000 Received: from GV1PR02MB8353.eurprd02.prod.outlook.com ([fe80::bac:5de1:56c4:91ac]) by GV1PR02MB8353.eurprd02.prod.outlook.com ([fe80::bac:5de1:56c4:91ac%3]) with mapi id 15.20.9870.023; Tue, 5 May 2026 09:56:42 +0000 Received: from GV1PR02MB8353.eurprd02.prod.outlook.com (2603:10a6:150:54::21) by PA4PR02MB6686.eurprd02.prod.outlook.com (2603:10a6:102:ff::14) with Microsoft SMTP Server (version=TLS1_2, cipher=TLS_ECDHE_RSA_WITH_AES_256_GCM_SHA384) id 15.20.9870.25; Tue, 5 May 2026 09:56:42 +0000 Received: from DU4PR02MB11713.eurprd02.prod.outlook.com (2603:10a6:10:637::24) by VI1PR02MB5024.eurprd02.prod.outlook.com with HTTPS; Tue, 5 May 2026 09:56:48 +0000 From: "Kristi Sarap - RA" To: "Margot Vent" References: In-Reply-To: Subject: =?utf-8?Q?Vs:_Meditsiiniuudised_p=C3=A4rivad?= Date: Tue, 5 May 2026 12:56:42 +0300 Message-ID: MIME-Version: 1.0 Content-Type: multipart/alternative; boundary="----=_NextPart_000_0075_01DCE3A1.7FA371D0" X-Mailer: Microsoft Outlook 16.0 Thread-Index: AQENhfB1LAc+zU3EhG+z2v1RMYkRCwJILsng Authentication-Results: spf=pass (sender IP is 13.93.42.39) smtp.mailfrom=ravimiamet.ee; dkim=none (message not signed) header.d=none;dmarc=none action=none header.from=ravimiamet.ee; X-MS-Has-Attach: X-MS-TNEF-Correlator: X-MS-Exchange-Organization-Network-Message-Id: 0bf484b7-847c-4bec-164e-08deaa8c9deb X-MS-Exchange-Organization-AuthSource: GV1PR02MB8353.eurprd02.prod.outlook.com X-MS-Exchange-Organization-AuthAs: Internal X-MS-Exchange-Transport-EndToEndLatency: 00:00:03.2961020 X-MS-Exchange-Processed-By-BccFoldering: 15.20.9870.020 Content-Language: et received-spf: Pass (protection.outlook.com: domain of ravimiamet.ee designates 13.93.42.39 as permitted sender) receiver=protection.outlook.com; client-ip=13.93.42.39; helo=westeu12-emailsignatures-cloud.codetwo.com; pr=C x-ms-exchange-organization-originalclientipaddress: 146.255.183.65 x-ms-exchange-organization-originalserveripaddress: 10.167.16.136 acceptlanguage: et-EE, en-US X-OlkEid: 000000004C30E2D3CD34B4428531CBEB8A7CAB89070034AD76187591974DBF6C4F76951C873A0100020000000000B04CDEF8D3227A448511457FBBCE9C870000000008940000127187AE445D264588D5B6CA11888B42 X-MS-Exchange-Organization-SCL: 1 X-MS-Exchange-Organization-MessageDirectionality: Originating X-MS-Exchange-Organization-AuthMechanism: 04 x-ms-traffictypediagnostic: GV1PR02MB8353:EE_|PA4PR02MB6686:EE_|AMS1EPF0000004B:EE_|DU4PR02MB11713:EE_|VI1PR02MB5024:EE_ X-MS-Office365-Filtering-Correlation-Id: 0bf484b7-847c-4bec-164e-08deaa8c9deb X-MS-Exchange-AtpMessageProperties: SA X-Microsoft-Antispam-Untrusted: BCL:0;ARA:13230040|39142699007|366016|31052699007|18002099003|8096899003|56012099003|22082099003|55112099003|41050700001; X-Microsoft-Antispam-Message-Info-Original: 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 X-Forefront-Antispam-Report-Untrusted: CIP:255.255.255.255;CTRY:;LANG:et;SCL:1;SRV:;IPV:NLI;SFV:NSPM;H:GV1PR02MB8353.eurprd02.prod.outlook.com;PTR:;CAT:NONE;SFS:(13230040)(39142699007)(366016)(31052699007)(18002099003)(8096899003)(56012099003)(22082099003)(55112099003)(41050700001);DIR:INT; X-Exchange-RoutingPolicyChecked: S8Err+PGIqb2TNa+gRX14SJdtQnj6w6U2mIoxBXEn2qbw1wejFwJY/ITb9AaORClJb+cSrPTjKwQQxik6SmIvEAc5OxOP8CBXh7K73Z0LMO0P48dQqQnkH7K6be+j5AkkWUHyJurIlloFme443n1RNo9g0opSqevKZ9O+VYCrrQp3NfZs8oLm3Trip/KwpuzOIXgz9TgNLZqde/+gQWcE6se49slOzpjHR5CrPKOvWjsPUQRTm9C6EwKV5orDFPrAqDEXishIhe9Tri/Z1XS2sT2O3sNCPBZHGc6KbXUL6DojHQba/PA0cqNqSXS33OsFVeYn1Ewac0VfWUEfOEHDA== X-MS-Exchange-Transport-CrossTenantHeadersStamped: DU4PR02MB11713 X-MS-Exchange-Transport-CrossTenantHeadersStamped: PA4PR02MB6686 X-OrganizationHeadersPreserved: PA4PR02MB6686.eurprd02.prod.outlook.com X-CodeTwo-MessageID: 96dcc581-c160-4d29-b200-9b7b6be4040b.20260505095644@westeu12-emailsignatures-cloud.codetwo.com X-CodeTwoProcessed: true X-MS-Exchange-Organization-ExpirationStartTime: 05 May 2026 09:56:45.4762 (UTC) X-MS-Exchange-Organization-ExpirationStartTimeReason: OriginalSubmit X-MS-Exchange-Organization-ExpirationInterval: 1:00:00:00.0000000 X-MS-Exchange-Organization-ExpirationIntervalReason: OriginalSubmit X-EOPAttributedMessage: 0 X-MS-Exchange-Organization-Recipient-P2-Type: Bcc X-CrossPremisesHeadersPromoted: AMS1EPF0000004B.eurprd04.prod.outlook.com X-CrossPremisesHeadersFiltered: AMS1EPF0000004B.eurprd04.prod.outlook.com X-MS-Exchange-Transport-CrossTenantHeadersStripped: AMS1EPF0000004B.eurprd04.prod.outlook.com X-MS-PublicTrafficType: Email X-OriginatorOrg: m1wmgpm3xrpm87txzdfw82by7.smtp.codetwo.online X-MS-Office365-Filtering-Correlation-Id-Prvs: bd3f8590-b72b-426d-499d-08deaa8c9c17 X-Microsoft-Antispam: BCL:0;ARA:13230040|35042699022|82310400026|31052699007|39142699007|366016|55112099003|8096899003|22082099003|18002099003|56012099003|41050700001; X-Forefront-Antispam-Report: CIP:13.93.42.39;CTRY:NL;LANG:et;SCL:1;SRV:;IPV:NLI;SFV:NSPM;H:westeu12-emailsignatures-cloud.codetwo.com;PTR:westeu12-emailsignatures-cloud.codetwo.com;CAT:NONE;SFS:(13230040)(35042699022)(82310400026)(31052699007)(39142699007)(366016)(55112099003)(8096899003)(22082099003)(18002099003)(56012099003)(41050700001);DIR:INT; X-MS-Exchange-CrossTenant-OriginalArrivalTime: 05 May 2026 09:56:45.4645 (UTC) X-MS-Exchange-CrossTenant-Network-Message-Id: 0bf484b7-847c-4bec-164e-08deaa8c9deb X-MS-Exchange-CrossTenant-Id: 8fe098d2-428d-4bd4-9803-7195fe96f0e2 X-MS-Exchange-CrossTenant-OriginalAttributedTenantConnectingIp: TenantId=8fe098d2-428d-4bd4-9803-7195fe96f0e2;Ip=[13.93.42.39];Helo=[westeu12-emailsignatures-cloud.codetwo.com] X-MS-Exchange-CrossTenant-AuthAs: Internal X-MS-Exchange-CrossTenant-AuthSource: GV1PR02MB8353.eurprd02.prod.outlook.com X-MS-Exchange-CrossTenant-FromEntityHeader: HybridOnPrem X-MS-Exchange-ExternalInOutlookResult: NotEnabled X-Microsoft-Antispam-Mailbox-Delivery: ucf:0;jmr:0;auth:0;dest:I;ENG:(910005)(944506478)(944626604)(920097)(425001)(930201)(20251009189)(140003); X-Microsoft-Antispam-Message-Info: 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 authentication-results-original: dkim=none (message not signed) header.d=none;dmarc=none action=none header.from=ravimiamet.ee; msip_labels: MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_Enabled=True;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_SiteId=8fe098d2-428d-4bd4-9803-7195fe96f0e2;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_SetDate=2026-05-05T09:56:41.545Z;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_Name=All Employees (unrestricted);MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_ContentBits=1;MSIP_Label_defa4170-0d19-0005-0004-bc88714345d2_Method=Standard; This is a multipart message in MIME format. ------=_NextPart_000_0075_01DCE3A1.7FA371D0 Content-Type: text/plain; charset="utf-8" Content-Transfer-Encoding: 8bit Tere, Margot! Ravimiameti poolt vastab meie õigusnõunik Heleni Mäe. "Seoses Euroopa Liidus äsja lõppenud ravimireformiga, muudeti muuhulgas ka direktiivi 2001/83/EU ravimireklaami reguleerivaid sätteid. Uue sätte alusel ei ole meditsiiniõed enam üldsus. Meditsiiniõed on edaspidi võrdsed arstide ja apteekritega ning kõik nimetatud koonduvad ühise nimetaja - tervishoiutöötajad - alla. Eesti toetas EL nõukogus Komisjoni esitatud ettepanekut retseptiravimite reklaami piirangute muutmise kohta, mis annab võimaluse avalikustada retseptiravimite reklaami ka meditsiiniõdedele. Eestis on piirangute muutmise vajadusest pikalt räägitud ning Ravimiamet on seda igati toetanud, tegime seda ka EL nõukogus Komisjoni ettepaneku poolt hääletades. Muudetud direktiivi rakendamiseks on vaja siseriiklikud õigusnormid üle vaadata ja kaasajastada. See ei puuduta ainult meditsiiniõdedele retseptiravimite reklaamimise õigust, vaid muudatusi on teisigi, millega senine ravimiseadus enam ei sobitu." Ikka head Kristi Sarap Ravimiameti kommunikatsiooninõunik kristi.sarap@ravimiamet.ee _____ Saatja: Margot Vent Saadetud: teisipäev, 5. mai 2026 09:36 Adressaat: Kristi Sarap - RA Teema: Meditsiiniuudised pärivad Tähelepanu! Tegemist on välisvõrgust saabunud kirjaga. Tundmatu saatja korral palume linke ja faile mitte avada. Tere, Kristi!Dr Diana Ingerainen esitas eile ravimiseaduse muudatuse, et õed saaks osaleda uusi ravimeid tutvustavatel koolitustel, mida korraldavad vastava müügiloaga ravimfirmad. Kas oleks võimalik saada kelleltki teist kommentaari, on sellest ka varem räägitud ja kuidas amet sellesse muudatusse suhtuks? Tagasisidet ootama jäädes Margot mu.ee-st ------=_NextPart_000_0075_01DCE3A1.7FA371D0 Content-Type: text/html; charset="utf-8" Content-Transfer-Encoding: quoted-printable
Tere, Margot!

Ravimiameti poolt vastab meie =C3=B5igusn=C3=B5unik Heleni = M=C3=A4e.

"Seoses Euroopa Liidus =C3=A4sja l=C3=B5ppenud ravimireformiga, = muudeti muuhulgas ka direktiivi 2001/83/EU ravimireklaami = reguleerivaid s=C3=A4tteid. Uue s=C3=A4tte alusel ei ole = meditsiini=C3=B5ed enam =C3=BCldsus. Meditsiini=C3=B5ed on edaspidi = v=C3=B5rdsed arstide ja apteekritega ning k=C3=B5ik nimetatud koonduvad =C3=BChise nimetaja - tervishoiut=C3=B6=C3=B6tajad - = alla.
Eesti toetas EL n=C3=B5ukogus Komisjoni esitatud ettepanekut = retseptiravimite reklaami piirangute muutmise kohta, mis annab = v=C3=B5imaluse avalikustada retseptiravimite reklaami ka = meditsiini=C3=B5dedele. Eestis on piirangute muutmise vajadusest = pikalt r=C3=A4=C3=A4gitud ning Ravimiamet on seda igati toetanud, tegime seda ka EL n=C3=B5ukogus Komisjoni = ettepaneku poolt h=C3=A4=C3=A4letades.
Muudetud direktiivi rakendamiseks on vaja siseriiklikud =C3=B5igusnormid = =C3=BCle vaadata ja kaasajastada. See ei puuduta ainult = meditsiini=C3=B5dedele retseptiravimite reklaamimise =C3=B5igust, vaid = muudatusi on teisigi, millega senine ravimiseadus enam ei = sobitu."


Ikka head
Kristi Sarap
Ravimiameti kommunikatsioonin=C3=B5unik
=
Saatja: Margot Vent = <Margot.Vent@aripaev.ee>
Saadetud: teisip=C3=A4ev, 5. mai 2026 09:36
Adressaat: Kristi Sarap - RA = <kristi.sarap@ravimiamet.ee>
Teema: Meditsiiniuudised p=C3=A4rivad
 

T=C3=A4helepanu! Tegemist on v=C3=A4lisv=C3=B5rgust saabunud kirjaga.
Tundmatu saatja korral palume linke ja faile mitte avada.
Tere, Kristi!=E2=80=8B

Dr Diana Ingerainen esitas eile ravimiseaduse muudatuse, et =C3=B5ed = saaks osaleda uusi ravimeid tutvustavatel koolitustel, mida korraldavad = vastava m=C3=BC=C3=BCgiloaga ravimfirmad. 

Kas oleks v=C3=B5imalik saada kelleltki teist kommentaari, on sellest ka = varem r=C3=A4=C3=A4gitud ja kuidas amet sellesse muudatusse = suhtuks?

Tagasisidet ootama j=C3=A4=C3=A4des

Margot 
mu.ee-st

------=_NextPart_000_0075_01DCE3A1.7FA371D0--